PLOD1 and metabolic syndrome: Its demonstrated efficacy in improving insulin sensitivity via reducing FINS by 31.8% and improving ISI by 66.3% in clinical trials, ameliorating dyslipidemia, reducing HA via decreasing testosterone and LH levels while increasing FSH, attenuating chronic inflammation and oxidative stress, restoring ovarian folliculogenesis and ovulation via normalizing estrous cycles and increasing high-quality oocyte rates, and modulating gut microbiota dysbiosis.